Acceleron Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XLRN Nasdaq 8731 http://www.acceleronpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acceleron Pharma Inc

2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line - Apr 22nd, 2018 5:15 am
Report: Developing Opportunities within Heico, Global Medical REIT, Acceleron Pharma, Momenta Pharmaceuticals, Silgan, and Weingarten Realty Investors — Future Expectations, Projections Moving into 2018 - Mar 20th, 2018 6:30 am
Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial - Mar 12th, 2018 5:00 am
High Growth NasdaqGM Stocks For The Day - Mar 6th, 2018 9:02 am
Edited Transcript of XLRN earnings conference call or presentation 27-Feb-18 10:00pm GMT - Feb 28th, 2018 4:11 pm
Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve - Feb 28th, 2018 5:04 am
Acceleron reports 4Q loss - Feb 27th, 2018 5:17 pm
Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results - Feb 27th, 2018 2:05 pm
Acceleron Pharma Inc to Host Earnings Call - Feb 27th, 2018 11:00 am
Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018 - Feb 20th, 2018 5:00 am
Acceleron Announces Appointment of Chief Commercial Officer - Feb 8th, 2018 2:01 pm
Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference - Jan 31st, 2018 5:00 am
Celgene's Investments Are Soaring - Jan 23rd, 2018 6:00 am
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy - Jan 8th, 2018 9:05 am
Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman - Jan 3rd, 2018 5:00 am
Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference - Jan 2nd, 2018 5:00 am
Acceleron Pharma Joins Rank Of Stocks With RS Ratings Over 90 - Dec 22nd, 2017 1:00 am
Acceleron Pharma Hits 80-Plus Relative Strength Rating Benchmark - Dec 21st, 2017 1:00 am
Stocks Showing Improved Relative Strength: Acceleron Pharma - Dec 19th, 2017 1:00 am